PUBLISHER: The Business Research Company | PRODUCT CODE: 1764277
PUBLISHER: The Business Research Company | PRODUCT CODE: 1764277
Celiac disease is an autoimmune condition in which the ingestion of gluten triggers an immune response that damages the small intestine, resulting in malabsorption and a range of symptoms. Diagnosis is typically confirmed through blood tests and intestinal biopsy, and the only effective treatment is a lifelong gluten-free diet to promote intestinal healing and prevent complications.
The primary treatments for celiac disease include infliximab, larazotide acetate, gluten-free diets, and other options. Infliximab is a monoclonal antibody that reduces inflammation by inhibiting tumor necrosis factor-alpha (TNF-a). It can be administered via oral or parenteral routes and is used across various settings, including hospitals, home care, and other healthcare facilities.
The celiac disease market research report is one of a series of new reports from The Business Research Company that provides celiac disease market statistics, including celiac disease industry global market size, regional shares, competitors with a celiac disease market share, detailed celiac disease market segments, market trends and opportunities, and any further data you may need to thrive in the celiac disease industry. This celiac disease market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The celiac disease market size has grown rapidly in recent years. It will grow from $0.71 billion in 2024 to $0.78 billion in 2025 at a compound annual growth rate (CAGR) of 10.4%. Growth during the historic period can be attributed to the increasing prevalence of celiac disease, greater awareness of gluten-related disorders, rising research funding for autoimmune conditions, a surge in food allergies and sensitivities, and a growing emphasis on consumer health consciousness.
The celiac disease market size is expected to see rapid growth in the next few years. It will grow to $1.15 billion in 2029 at a compound annual growth rate (CAGR) of 10.1%. The projected growth in the forecast period can be attributed to the increasing demand for personalized medicine, expansion of healthcare infrastructure, growing need for nutritional counseling services, rising rates of pediatric diagnoses, and a greater focus on early-life screening and preventive measures. Key trends expected during this period include wider availability of diagnostic testing, advancements in genetic testing technologies, enhanced screening protocols in primary care, innovations in ELISA and serological testing methods, and the adoption of non-invasive diagnostic approaches.
The expansion of personalized medicine is expected to contribute significantly to the growth of the celiac disease market in the coming years. Personalized medicine is a healthcare approach that tailors medical treatment to an individual's genetic makeup, environment, and lifestyle. The rising demand for personalized medicine is driven by the growing accessibility of genetic testing, which facilitates more accurate diagnoses and personalized treatment plans based on individual patient profiles. In the context of celiac disease, personalized medicine enables precise identification of genetic markers and specific immune responses, resulting in more targeted and effective treatment strategies. For example, in February 2024, the Personalized Medicine Coalition, a US-based nonprofit organization, reported that the FDA approved 16 personalized therapies for rare diseases in 2023, up from 6 in 2022. Thus, the growth of personalized medicine is expected to propel the celiac disease market forward.
Leading companies in the celiac disease market are concentrating on the development of advanced therapies, such as anti-interleukin-15 (IL-15) antibodies, to minimize tissue damage by regulating excessive immune cell activity. Anti-interleukin-15 (IL-15) antibodies are targeted proteins that block the action of the IL-15 cytokine, thereby helping to modulate immune responses and reduce inflammation. For example, in May 2025, Teva Pharmaceutical Industries, a pharmaceutical company based in Israel, announced that the U.S. Food and Drug Administration had granted Fast Track designation to TEV-53408, an investigational anti-interleukin-15 (IL-15) antibody. This monoclonal antibody is being developed for patients with celiac disease who continue to experience symptoms despite adhering to a gluten-free diet. It works by inhibiting interleukin-15 (IL-15), a key molecule responsible for triggering the immune response that causes intestinal damage in celiac disease. TEV-53408 is currently being evaluated in a Phase 2a clinical trial to assess its safety and efficacy.
In May 2025, Targeted Genomics, a US-based company specializing in celiac disease genetics and wellness, entered into a partnership with OraSure Technologies to provide direct-to-consumer (DTC) genetic testing for celiac disease. This collaboration allows Targeted Genomics to work alongside an experienced industry leader to advance their mission. The partnership reinforces their goal of delivering genetic risk information directly to individuals who are proactive about their health. OraSure Technologies is a US-based company that offers diagnostic solutions for celiac disease.
Major players in the celiac disease market are Pfizer Inc., Sanofi SA, Novartis AG, Takeda Pharmaceutical Company Ltd., Chugai Pharmaceutical Co. Ltd., Dr Falk Pharma GmbH, Theriva Biologics Inc., Equillium Inc., Immunic Inc., Barinthus Biotherapeutics Plc, Allero Therapeutics, Anokion SA, Mozart Therapeutics, ImmunogenX, Topas Therapeutics GmbH, Parvus Therapeutics Inc., AMYRA Biotech AG, Provention Limited, Precigen Inc., Zedira GmbH, AnTolRx Inc., Nemysis Ltd., Entero Therapeutics Inc.
North America was the largest region in the celiac disease market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in celiac disease report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the celiac disease market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The celiac disease market consists of revenues earned by entities by providing services such as diagnostic testing services, histopathology services, dietary consultation, nutrition counseling, and food certification. The market value includes the value of related goods sold by the service provider or included within the service offering. The celiac disease market also includes sales of gluten-free foods, diagnostic test kits, nutritional supplements, gluten detection devices, and probiotics. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Celiac Disease Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on celiac disease market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Where is the largest and fastest growing market for celiac disease ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The celiac disease market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.